UNITED STATES Country 8079710 Patent Number
FRANCE Country 1331884 Patent Number
UNITED KINGDOM Country 1331884 Patent Number
GERMANY Country 60145133-3 Patent Number
GERMANY Country 60149158-0 Patent Number
UNITED STATES Country 6656131 Patent Number
GERMANY Country 60348119-1 Patent Number
FRANCE Country 1485006 Patent Number
UNITED KINGDOM Country 1485006 Patent Number
JAPAN Country 4484523 Patent Number
UNITED STATES Country 7220000 Patent Number
AUSTRALIA Country 2002210874 Patent Number
JAPAN Country 4362287 Patent Number
UNITED STATES Country 7275830 Patent Number
FRANCE Country 1624794 Patent Number
UNITED KINGDOM Country 1624794 Patent Number
GERMANY Country 602004038437-2 Patent Number
UNITED STATES Country 7665847 Patent Number

FDA Indication for Use

The ForeseeHome is intended for use in the detection and characterization of central and paracentral metamorphopsia (visual distortion) in patients with age-related macular degeneration, as an aid in monitoring progression of disease factors causing metamorphopsia including but not limited to choroidal neovascularization (CNV). It is intended to be used at home for patients with stable fixation.

The ForeseeHome AMD Monitoring Program is only available by physician order and is intended to be used as an addition to regular eye exams.

The ForeseeHome AMD Monitoring Program is covered by Medicare, subject to its coverage requirements for the test, to assess patients with dry AMD who are at risk of developing wet AMD.